The October 22 sell-off was a price correction, not a refutation of the thesis. Meta, Lam Research and Tesla all reported stronger demand. What changed was the cost of capital: Meta's free cash flow turned negative and Jensen Huang said "capital is scarce." Of seven testable sub-claims behind the abundance thesis, five were validated and two were challenged (capital supply and timelines). None was falsified.
Key signals
- The Philadelphia Semiconductor Index fell 6.72% and the Nasdaq 2.60%, the Nasdaq's largest drop since June. The semiconductor index now sits only 0.7% above its 200-day line (10,658).
- Meta's Q3 revenue was $64.60B (+26%) and ad prices rose 14%. Capex was $34.91B and free cash flow was -$2.12B. Meta also plans a non-voting Class C share from January 2027, partly to raise capital.
- Lam sees 2027 wafer-fab equipment (WFE) spending above $200B. TrendForce expects Q4 DRAM contract prices to rise 20% from Q3.
- The 10-year Treasury yield fell 17bp to 4.96%, and Brent crude rose 4% to $113.17.
- The Hang Seng fell 3.03% to 22,934.68 and ChiNext fell 4.37%. Northbound flows were negative for a seventh straight day.
By theme
AI
Meta's 14% rise in ad prices is the clearest evidence yet that AI spending turns into revenue. The open question is timing, because investment is running ahead of returns. OpenAI is reportedly near a raise of up to $30B at a $1.25T pre-money valuation, down from the $1.4T reported a month earlier. OpenAI models are now available on Google Cloud. DeepSeek's DeepInfer framework supports Huawei Ascend chips at launch. Microsoft and Alphabet report on October 28, the next major test of returns on capex.
Robotics
Tesla says the first production-quality Optimus robots came off a Fremont high-volume line, and Musk targets 20,000 a week in about a year. Tesla also cut 2026 capex guidance to about $20B, which sits awkwardly with a production ramp. Chinese A-share robotics stocks rallied against a falling market.
Space
SpaceX (SPCX) fell 9.14% after Tesla insiders voiced worries about governance if the two companies merge. Rocket Lab pushed Neutron's first flight to 2027, its fourth delay. Private funding stayed strong: Xona raised $250B at a $2.45B valuation and Varda raised $251M.
Biotech
Healthcare was among the few rising sectors (+0.80%). Data on Moderna and Merck's personalized mRNA vaccine leaked early: it cut melanoma recurrence or death risk by 42%. Moderna still fell 17.57%, because the stock was already up 587% this year. ESMO runs October 23–27, with Akeso and Innovent readouts due.
Hong Kong, A-shares and crypto
Chinese AI platforms are being re-priced on profits. Alibaba's net profit fell 49.7%, and Tencent hit a 52-week low. Optical-module leaders fell sharply: Eoptolink dropped 12.28% and Zhongji Innolight 8.76%. Bitcoin fell 3.15% to $81,244.5, below the $82,500 support level. AI tokens fell roughly twice as much as Bitcoin.
Rating highlights
| Ticker | Company | Call | Why |
|---|---|---|---|
| META:NASDAQ | Meta | Buy | Ad prices +14% prove AI monetization; forward P/E 19.1 already discounts negative FCF |
| NVDA:NASDAQ | Nvidia | Buy | Hyperscaler capex still rising; "capital scarcity" applies to neoclouds; stop 205.18 |
| LRCX:NASDAQ | Lam Research | Buy | 2027 WFE outlook above $200B; forward P/E 18.9, RSI oversold; small position |
| MU:NASDAQ | Micron | Buy | DRAM price rises and capacity growth both confirmed; forward P/E 4.07 |
| TSM:NYSE | TSMC | Buy (upgraded) | Back in entry range; ten new fabs in 2027 support demand; stop 389.36 |
| 3692:HKEX | Hansoh Pharma | Buy (upgraded) | Roche ADC deal brings $400M upfront cash |
| 9926:HKEX | Akeso | Buy | Head-to-head overall-survival win in biliary cancer; ESMO data is a binary risk |
| 603986:SSE | GigaDevice | Buy | Memory price rises confirmed; forward P/E 13.4; stop 259.31 |
| GFS:NASDAQ | GlobalFoundries | Sell (downgraded) | Broke its stop; revenue up only 5.8%, so the AI spillover thesis is falsified |
| VST:NYSE | Vistra | Sell (downgraded) | Broke its stop at 143.00; thesis intact, discipline first |
| 1024:HKEX | Kuaishou | Sell (downgraded) | Closed below its 27.07 stop; trend has not stopped falling |
| MRNA:NASDAQ | Moderna | Sell | Strong data already priced in; average target 35% below the current price |
| ASTS:NASDAQ | AST SpaceMobile | Sell | 130x sales leaves no room for competition from SpaceX Starlink |
| MSFT:NASDAQ | Microsoft | Watch (downgraded) | Just below its entry range; wait for October 28 earnings |
| TER:NASDAQ | Teradyne | Watch (downgraded) | Broke its candidate stop; reassess after October 27 earnings |
Tenbagger radar
- BKSY:NYSE (BlackSky), entered: AI-driven satellite imagery with a 69.9% gross margin. Its assumed path gives roughly 5.9x on a fully diluted basis. It exits if quarterly growth drops below 25% before Q2 2027.
- 9880:HKEX (UBTech), entered: the purest Hong Kong humanoid-robot name, with revenue up 104%. It was admitted as an exception: cash covers only about 1.8 years, so dilution risk is flagged.
- AXTI:NASDAQ, rejected: the path implies only 3.3x, and 26.9x sales already prices in years of growth.
- LUNR:NASDAQ, rejected: 4.9x diluted, just below the 5x bar, with negative equity.
- 2498:HKEX, rejected: revenue growth is under 30%.
- RKLB:NASDAQ, rejected: market cap is above the threshold.
- 688017:SSE, rejected: a 330x P/E implies only 1.7x upside.
- 688297:SSE, rejected: a 9.4% gross margin caps the upside at about 2.1x.
Risks to watch
- On October 28, Microsoft and Alphabet report and the FOMC decides on rates. Amazon and Intel report October 29.
- If the semiconductor index closes below 10,658, a medium-term correction is confirmed technically.
- Capital supply: Meta's negative free cash flow, and neocloud debt yields near 16% (CoreWeave).
- ESMO readouts: Moderna's formal data on October 24 and Akeso on October 25. For Singapore investors, MAS treats unregulated stablecoins and other crypto tokens as high-risk assets.